Integra lifesciences
Integra LifeSciences Holdings Corporation, commonly referred to as Integra, is a prominent player in the medical technology industry, headquartered in the United States. Founded in 1989, the company has established itself as a leader in regenerative medicine and neurosurgery, with a strong presence in North America, Europe, and Asia. Integra's core offerings include advanced wound care products, neurosurgical solutions, and surgical instruments, distinguished by their innovative designs and commitment to improving patient outcomes. The company is particularly noted for its Integra Dermal Regeneration Template, which has revolutionised the treatment of complex wounds. With a robust market position, Integra has achieved significant milestones, including strategic acquisitions that have expanded its product portfolio and global reach. As a trusted partner in healthcare, Integra LifeSciences continues to drive advancements in surgical and regenerative solutions, enhancing the quality of care for patients worldwide.
DitchCarbon Score
How does Integra lifesciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Integra lifesciences's score of 19 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Integra lifesciences's reported carbon emissions
In 2023, Integra LifeSciences reported total carbon emissions of approximately 156,706,000 kg CO2e from Scope 3, alongside 8,277,000 kg CO2e from Scope 1 and 15,333,000 kg CO2e from Scope 2. This marks a significant reduction in Scope 1 emissions from 13,215,000 kg CO2e in 2022 and a decrease in Scope 2 emissions from 16,210,000 kg CO2e in the same year. In 2022, the company’s total emissions were approximately 158,981,000 kg CO2e for Scope 3, 13,215,000 kg CO2e for Scope 1, and 16,210,000 kg CO2e for Scope 2. The trend indicates a commitment to reducing emissions across all scopes, particularly in direct emissions (Scope 1) and indirect emissions from energy consumption (Scope 2). Despite these reductions, Integra LifeSciences has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of formal reduction targets suggests a need for further commitment to climate action within the industry context. Overall, the company is making strides in reducing its carbon footprint, aligning with broader industry efforts to address climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 13,902,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 18,609,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Integra lifesciences is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
